AUDUBON, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Jefferies Global Healthcare Conference in London.
Globus Medical NYSE: GMED lowered its 2026 revenue forecast after third-quarter sales fell, citing continued declines at its Nevro business, delayed spine product launches and lower contributions from competitive sales recruiting.
Globus Medical cuts its 2026 revenue outlook amid spine launch delays and weak Nevro sales while shifting its focus to new products and growth opportunities in 2027.
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.18 per share a year ago.
AUDUBON, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended September 30, 2026.
Globus Medical is leveraging flexible leasing models to expand its installed base, prioritizing recurring high-margin implant sales over upfront capital revenue. GMED's post-NuVasive integration is driving structurally higher margins, with adjusted EBITDA margins rising to 35.4% and free cash flow nearly doubling year-over-year. Despite a segment revenue decline, ExcelsiusGPS placements grew 25%, supporting a transition to a more recurring, cash-generative business model.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for those looking for undervalued stocks?